Leukocyte Telomere Length as a Molecular Biomarker of Coronary Heart Disease

Genes (Basel). 2022 Jul 12;13(7):1234. doi: 10.3390/genes13071234.

Abstract

Background: This work is a review of preclinical and clinical studies of the role of telomeres and telomerase in the development and progression of coronary heart disease (CHD).

Materials and methods: A search for full-text publications (articles, reviews, meta-analyses, Cochrane reviews, and clinical cases) in English and Russian was carried out in the databases PubMed, Oxford University Press, Scopus, Web of Science, Springer, and E-library electronic library using keywords and their combinations. The search depth is 11 years (2010-2021).

Results: The review suggests that the relative leukocyte telomere length (LTL) is associated with the development of socially significant and widespread cardiovascular diseases such as CHD and essential hypertension. At the same time, the interests of researchers are mainly focused on the study of the relative LTL in CHD.

Conclusions: Despite the scientific and clinical significance of the analyzed studies of the relative length of human LTL as a biological marker of cardiovascular diseases, their implementation in real clinical practice is difficult due to differences in the design and methodology of the analyzed studies, as well as differences in the samples by gender, age, race, and ethnicity. The authors believe that clinical studies of the role of the relative length of leukocyte telomeres in adult patients with coronary heart disease are the most promising and require large multicenter studies with a unified design and methodology.

Keywords: acute coronary syndrome; acute myocardial infarction; adults; coronary atherosclerosis; early vascular aging; molecular predictors; people; stable coronary heart disease; telomere length.

Publication types

  • Review

MeSH terms

  • Adult
  • Biomarkers
  • Cardiovascular Diseases*
  • Coronary Disease* / genetics
  • Humans
  • Leukocytes
  • Telomere / genetics

Substances

  • Biomarkers

Grants and funding

This research received no external funding.